{
    "clinical_study": {
        "@rank": "139684", 
        "acronym": "PBC", 
        "arm_group": {
            "arm_group_label": "Abatacept 125 mg weekly", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if abatacept (Orencia) is effective in patients\n      with primary biliary cirrhosis who do not respond adequately to standard treatment with\n      ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall)."
        }, 
        "brief_title": "Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis", 
        "condition": "Primary Biliary Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis, Biliary", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label, active treatment trial to assess the efficacy and safety of abatacept\n      in subject with PBC who have had an incomplete biochemical response to UDCA. In this trial,\n      20 subjects with PBC who have had an incomplete biochemical response to UDCA will be\n      assigned to treatment with weekly subcutaneous injections of 125 mg of abatacept. The\n      treatment phase of the study will last 24 weeks with an off-treatment follow up at Week 36.\n\n      Inclusion criteria include:\n\n        -  Confirmed diagnosis of PBC\n\n        -  Alkaline phosphatase > 1.67 times the upper limit of normal after 6 months of treatment\n           with UDCA"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed PBC diagnosis based upon at least 2 of 3 criteria\n\n               1. Anti-mitochondrial antibody (AMA) titer > 1:40\n\n               2. Alkaline phosphatase > 1.5 times the upper limit of normal for at least 6 months\n\n               3. Liver biopsy findings consistent with PBC\n\n          -  Incomplete response to UDCA defined by an alkaline phosphatase > 1.67 X the upper\n             limit of normal after 6 months of UDCA at a minimum dose of 13 mg/kg/d\n\n          -  Taking a stable dose of UDCA for at least 3 months prior to Day 0\n\n          -  aspartate aminotransferase (AST) and alanine aminotransferase ALT < 5 times the upper\n             limit of normal\n\n        Exclusion Criteria:\n\n          -  Presence of concomitant liver diseases including viral hepatitis, primary sclerosing\n             cholangitis, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's\n             syndrome.\n\n          -  Prior liver transplantation\n\n          -  Decompensated liver disease\n\n          -  Use of immunosuppressants within 6 months of Day 0\n\n          -  Use of biologic agents within 12 months of Day 0"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078882", 
            "org_study_id": "IM101-457"
        }, 
        "intervention": {
            "arm_group_label": "Abatacept 125 mg weekly", 
            "description": "125 mg subcutaneously each week for 24 weeks", 
            "intervention_name": "abatacept", 
            "intervention_type": "Biological", 
            "other_name": "Orencia"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ursodeoxycholic Acid", 
                "Cytotoxic T-lymphocyte antigen 4", 
                "Abatacept"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary Biliary Cirrhosis", 
            "Ursodeoxycholic acid", 
            "Abatacept", 
            "Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "link": {
            "description": "PBC Patient Organization", 
            "url": "http://www.pbcers.org"
        }, 
        "location": {
            "contact": {
                "email": "sandeep.dhaliwal@ucdmc.ucdavis.edu", 
                "last_name": "Sandeep Dhaliwal, MD", 
                "phone": "916-734-8985"
            }, 
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95817"
                }, 
                "name": "Univeristy of California Davis Medical Center"
            }, 
            "investigator": {
                "last_name": "Lorenzo Rossaro, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "ABATACEPT FOR THE TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH AN INCOMPLETE BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID", 
        "other_outcome": [
            {
                "description": "Change in anti-mitochondrial antibody titers form Day 0 to Week 24.", 
                "measure": "Anti-mitochondrial antibody titers", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Change in IgM level from Day 0 to Week 24", 
                "measure": "Immunoglobulin M (IgM) Levels", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Change in cluster of differentiation 4 (CD4)+ cluster of differentiation 44 (CD44)+ cluster of differentiation 62 ligand (CD62L)- and cluster of differentiation 8+ CD44+ CD62L- frequencies in peripheral blood mononuclear cells from Day 0 to Week 24", 
                "measure": "Memory T cell frequencies", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }
        ], 
        "overall_contact": {
            "email": "sandeep.dhaliwal@ucdmc.ucdavis.edu", 
            "last_name": "Sandeep Dhaliwal, MD", 
            "phone": "916-734-8985"
        }, 
        "overall_contact_backup": {
            "email": "mia.minoletti@ucdmc.ucdavis.edu", 
            "last_name": "Mia Minoletti, PhD", 
            "phone": "916-734-8851"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, Davis", 
                "last_name": "Christopher L Bowlus, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, Davis", 
                "last_name": "M. Eric Gershwin, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Normalization of alkaline phosphatase or decrease of alkaline phosphatase by > 40% of the Day 0 level at 24 weeks of treatment.", 
            "measure": "Biochemical Response", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078882"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety outcomes include adverse events, clinically significant changes in vital signs, laboratory test abnormalities, and clinical tolerability of the drug.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 2, 4, 12, 24, and 36"
            }, 
            {
                "description": "The absolute and percent change in alkaline phosphatase from Day 0 to Week 24.", 
                "measure": "Absolute and percent change in alkaline phosphatase", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "The absolute and percent change in alanine transferase (ALT) from Day 0 to Week 24.", 
                "measure": "Absolute and percent change in alanine transferase (ALT)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Change in liver stiffness measured by magnetic resonance elastography from Day 0 to Week 24.", 
                "measure": "Liver stiffness measured by magnetic resonance elastography", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Change in quality of life measured by change in PBC-40 from Day 0 to Week 24.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Frequency and titer of anti-abatacept antibody at Day 0 and Week 24", 
                "measure": "Anti-abatacept titers", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Trough levels of abatacept at Day 0 and Weeks 4, 12, 24, and 36.", 
                "measure": "Abatacept levels", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 12, 24, and 36"
            }
        ], 
        "source": "University of California, Davis", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, Davis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}